Authors:
Tefferi, A
Jimenez, T
Gray, LA
Mesa, RA
Chen, MG
Citation: A. Tefferi et al., Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia, EUR J HAEMA, 66(1), 2001, pp. 37-42
Authors:
Mesa, RA
Tefferi, A
Elliott, MA
Hoagland, HC
Call, TG
Schroeder, GS
Yoon, SY
Li, CY
Gray, LA
Margolin, S
Hook, CC
Citation: Ra. Mesa et al., A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia, BR J HAEM, 114(1), 2001, pp. 111-113
Authors:
Tefferi, A
Elliott, MA
Yoon, SY
Li, CY
Mesa, RA
Call, TG
Dispenzieri, A
Citation: A. Tefferi et al., Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia, BLOOD, 97(6), 2001, pp. 1896-1896
Citation: Ra. Mesa et al., Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia, BLOOD, 97(11), 2001, pp. 3665-3667
Authors:
Mesa, RA
Hanson, CA
Rajkumar, SV
Schroeder, G
Tefferi, A
Citation: Ra. Mesa et al., Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia, BLOOD, 96(10), 2000, pp. 3374-3380
Authors:
Tefferi, A
Mesa, RA
Nagorney, DM
Schroeder, G
Silverstein, MN
Citation: A. Tefferi et al., Splenectomy in myelofibrosis with myeloid metaplasia: a single-institutionexperience with 223 patients, BLOOD, 95(7), 2000, pp. 2226-2233
Authors:
Mesa, RA
Silverstein, MN
Jacobsen, SJ
Wollan, PC
Tefferi, A
Citation: Ra. Mesa et al., Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County study, 1976-1995, AM J HEMAT, 61(1), 1999, pp. 10-15
Citation: Sy. Yoon et al., Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia, BR J HAEM, 106(3), 1999, pp. 682-688